Hajer Rahali-Khachlouf
Sonia Hamdoun
Imen Miri
Sonia Lebib
Thouraya Bouaziz
Fatma Zohra Ben Salah
Catherine Dziri


Objective: To assess functional impairment in patients with rheumatoid pelvispondylite. Patients and methods: cross-sectional study conducted on patients with rheumatoid pelvispondylite. Data are collected in a form specifying the epidemiological and demographic data, disease activity by Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI), metrological static and dynamic examination. Evaluation of functional impairment by Bath Ankylosing Spondylitis Functional Index (BASFI), and likert scale assessing social, economic and physical disability.
Results: 30 patients (22 men), the mean age is 37.2 years old; twenty one patients are without work. The mean duration of disease is 13.36 years, 50% are annoyed by morning stiffness than one hour, spinal pain and fatigue. The average value of BASDAI is 43.72 / 100; the average value of EVA fatigue is 56.16 / 100. The average value of BASFI is 56.36 / 100. An important or very important social, economic and physical disability was felt among 67% of the patients, which is correlated with duration of the disease, the BASDAI index, work, and the BASFI index.
Conclusion: The functional impairment caused is statistically correlated with the intensity of the pain, the fatigue, the morning stiffness and BASDAI index. This impact on the quality of life is increased by the low level of education and poor professional integration.


rheumatoid Pelvispondylite, clinical status; functional impairment



  1. Ariza-Ariza R, H ernandez-Cruz B, Navarro-Sarabia F. Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis. Arthritis Rheum 2003; 49:483-487
  2. Barlow J H, wright CC, williams B, Keat A. Work disability among people with ankolosing spondylitis. Arthritis Rhum 2001; 45: 424-429
  3. Boonen A, Chorus A, Miedema H, Vander Heijde D, Landewé R and all. Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. Ann Rheum Dis 2001; 60: 1033-1039.
  4. Bosten EE, Borman P, Bodur H,Barca N. Functional disability and quality of life in patients with ankylosing spondylitis. Rheumatol Int 2004; 23:121-126
  5. Braun J, sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides : established medical treatment , anti -TNF alpha therapy and other novel approaches. Arthritis Res 2002; 4:307-21
  6. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, Westlake L. Validating the SF 36 health survey questionnaire: new outcome measure for primary care. BMJ 1992; 305:160-164
  7. Cello D, Nowinsky CJ. Measuring quality of life in chronic illness : the functional assessment of chronic illness therapy measurement system. Arch Phys Med Rehabil 2002; 83: 10- 17
  8. Chorus AM, Miedema HS, Boonen A, Van Der Linden S. Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis 2003; 62:1178-1184
  9. Dagfinrud H, kjeken I , Mowinckel P, Hagen KB, kviem TK. Impact of functionnal impairment in ankylosing spondylites impairment , activity, limitation, and participation restrictions. J Rheumatol 2005; 32: 516-523
  10. Doward LC, Spoorenberg A, c ook SA , whalley D, Helliwell PS, Kay LJ et al. Development of the ASQOL a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003; 62: 20-26
  11. Forejtova S, Mann H , Stolfa J , K verdal Fenclova I, Nemethova D, Pavelka k. Factors influencing health status and disability of patients with ankylosing spondylitis in the Czech. Republic. Clin Rhumatol 2008; 5 (Epub a head of print)
  12. Gorman JD, Sack KE, Davis Jc Jr . Treatment of antkylosing spondylitis by inhibition of tumor necrosis factor alpha. N engl J Med 2002; 346: 1349-56
  13. Hays RD, Hahm H, Marsh all G. Use of the SF 36 and other health related quality of life measures to assess persons with disabilities. Arch Phys Med Rehabil 2002; 83: 4-9
  14. Husted JA, Gladman DD, Farewell VT, Long JA, Cook RJ Validating the SF-36 Health Survey Questionnaire in patients with psoriatic arthritis. J Rheumatol 1997; 24:511-517
  15. Ozgul A, Peker F , taskaynatan MA, Tan AK , Dincer k, Kalyon TA. Effect of ankylosing spondylitis on health related quality of life and different aspects of social life in young patients Clin Rheumatol 2006; 25: 168-174
  16. The WHOQOL Group. What quality of life. World health forum 2000; 17: 354-355
  17. Toussirot E, wendling D. Current guidelines for the drug treatment of ankylosing spondylitis. Drugs 1998; 56:225-40
  18. Ware JE Jr. SF-36 Health Survey Update. Spine 2000; 25:3130-3139
  19. Ward MM. Quality of life in patients with ankylosing spondylitis. Rheum Dis Clin North Am 1998; 24:815-827
  20. Ward MM. Health-Related quality of life in AnkylosingSpondylitis : A survey of 175 patients. Arthritis care and research 1999; 12:247-255
  21. Ward M, Kusis S. Risk factors for work disability in patients with ankylosing spondylitis. J Rheumatol 2001; 28: 315-321.
  22. Ward MM, Weisman MH, Davis JC, Reveille JD. Risk factors for functional limitations in patients with long standing ankylosing spondylitis. Arthritis Rheum 2005; 53: 710-717.
  23. Yasemin Turan , Mehmet Tuncay Duruoez, Lale Cerra hogen. Quality of life in patients with ankylosing spondylitis : a pilot study Rheumatol Int 2007; 27 : 895-899
  24. Zabo S. The world health organisation quality of life assessment instrument. In : spilker B Quality of life and pharmacoeconomics in clinical trials, 2nd edn lippincott - Raven, Philadelphia, 1996; pp 355-362
  25. Zink A, Braun J, Listing J, Wollenhaupt J, German collaborative arthritis centers; Disability and handicap in rheumatoid arthritis and ankylosing spondylitis , results from the german rheumatological database. J Rheumatol 2OOO; 27: 613-622